Janina Golob Deeb, Sara Kube, Caroline Kelly Carrico, Sarah Glass, Kinga Grzech-Leśniak
{"title":"Association between COVID-19 vaccination, SARS-CoV-2 infection, and oral lichen planus (OLP) flares: Results from a patient survey.","authors":"Janina Golob Deeb, Sara Kube, Caroline Kelly Carrico, Sarah Glass, Kinga Grzech-Leśniak","doi":"10.17219/acem/217201","DOIUrl":"https://doi.org/10.17219/acem/217201","url":null,"abstract":"<p><strong>Background: </strong>Oral lichen planus (OLP) is a chronic immune-mediated mucocutaneous disease. During the COVID-19 pandemic, new cases and flares of OLP were reported after SARS-CoV-2 infection or vaccination. Immune activation and cytokine release triggered by infection or vaccines are proposed mechanisms, although current evidence is limited. Clarifying this relationship is important for improving patient counseling and management during vaccination efforts.</p><p><strong>Objectives: </strong>The study aimed to explore the association with an increased occurrence of OLP flares following COVID-19 vaccination or infection.</p><p><strong>Material and methods: </strong>An 11-question survey was distributed to OLP patients. The questionnaire aimed to inquire about the history of COVID-19 vaccination and infection as it related to subjective flares of OLP (oral redness, ulcerations, pain, or discomfort). Associations with complications were assessed with Fisher's exact or Wilcoxon tests.</p><p><strong>Results: </strong>Seventy-six patients participated in the survey. Twenty percent of study participants reported experiencing a flare after COVID-19 vaccination (n = 13), and 33% after an infection (n = 13). Self-reported OLP flares were significantly associated with whether or not participants also reported vaccine side effects (p = 0.005). Among the 27 participants who reported experiencing systemic post-vaccination side effects (tiredness, headache, muscle pain, chills, fever, nausea), 37% (n = 10) also reported an OLP flare compared with 8% (n = 3) of the 38 who did not report systemic side effects from the COVID-19 vaccination. Of the 63 participants who received a 2nd vaccine dose, 21% (n = 13) reported experiencing an OLP flare. Experiencing systemic side effects following the 2nd vaccination was again significantly associated with reporting an OLP flare (p = 0.048).</p><p><strong>Conclusions: </strong>Overall, OLP flares were not reported at high rates with COVID-19 vaccination or infection. Within these limitations, the findings of the study suggest that participants who experience systemic side effects following a COVID-19 vaccine may be more susceptible to OLP flares. Experiencing an OLP flare following the 1st COVID-19 vaccination was significantly associated with experiencing a flare again after receiving the 2nd vaccination.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka
{"title":"Herpes zoster epidemiology during and after the COVID-19 pandemic: A 5-year retrospective study from primary care in Poland.","authors":"Michał Oleszko, Lech Zaręba, Aleksandra Łoś, Nikola Król, Hanna Czajka","doi":"10.17219/acem/222571","DOIUrl":"https://doi.org/10.17219/acem/222571","url":null,"abstract":"<p><strong>Background: </strong>Herpes zoster (HZ) is caused by reactivation of latent varicella-zoster virus and affects 25-30% of individuals, with the highest incidence in adults aged ≥50 years and a lifetime risk exceeding 50% after the age of 85. Its most common complication is postherpetic neuralgia (PHN), i.e., persistent neuropathic pain. Reports of increased HZ incidence during or after SARS-CoV-2 infection suggest potential epidemiological associations requiring further investigation.</p><p><strong>Objectives: </strong>Our goals were to evaluate the incidence of HZ and its complications during the pandemic and the post-pandemic period in primary care settings in Poland.</p><p><strong>Material and methods: </strong>We conducted a retrospective multicenter study in 20 primary care clinics in Poland, covering 43,949-81,091 patients from 2020 to 2024. Incident HZ cases and complications (PHN, herpes zoster ophthalmicus (HZO), HZ oticus, and disseminated HZ) were identified, and demographic data, including place of residence, were collected. Statistical analyses included χ2 or Fisher's exact tests, Student's t-tests or nonparametric equivalents, odds ratios (ORs) with 95% confidence intervals (95% CIs), and receiver operating characteristic (ROC) analysis to assess age-related risk of prolonged symptoms.</p><p><strong>Results: </strong>A total of 570 HZ cases were recorded from 2020 to 2024. Incidence ranged from 1.61 to 2.14 per 1,000 persons and increased with age, reaching 6.57 per 1,000 in individuals aged ≥80 years. Patients aged ≥71 years had higher odds of developing PHN (pain persisting for >90 days) than younger patients (OR = 4.47; 95% CI: 2.30-8.67; p < 0.001). Older adults were also more likely to develop HZO (p = 0.001). Rural incidence was significantly lower during the pandemic than in the post-pandemic period (p = 0.005), with no significant differences in urban or semi-urban areas.</p><p><strong>Conclusions: </strong>The risk of HZ, PHN, and HZO rises with age. During the pandemic (2020-2021), rural incidence was significantly lower than in the post-pandemic period (2022-2024). The study provides updated data on HZ epidemiology in Poland and highlights the impact of the COVID-19 pandemic on healthcare access and HZ reporting in rural areas.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tomasz Marjański, Natalia Szczepańska, Julia Niedzielska, Aleksandra Ciarka, Rafał Pęksa, Aleksandra Czapla, Renata Świątkowska-Stodulska, Ewa Milnerowicz-Nabzdyk
{"title":"A multidisciplinary diagnostic approach to thoracic endometriosis syndrome: Insights from CT imaging, surgery, and pathology.","authors":"Tomasz Marjański, Natalia Szczepańska, Julia Niedzielska, Aleksandra Ciarka, Rafał Pęksa, Aleksandra Czapla, Renata Świątkowska-Stodulska, Ewa Milnerowicz-Nabzdyk","doi":"10.17219/acem/217291","DOIUrl":"https://doi.org/10.17219/acem/217291","url":null,"abstract":"<p><strong>Background: </strong>Thoracic endometriosis syndrome (TES) is the most common extrapelvic manifestation of endometriosis, yet its classification, diagnosis, and treatment remain debated. Thoracic endometriosis syndrome has recently been proposed to be categorized into 3 types: pleural, bronchopulmonary, and diaphragmatic.</p><p><strong>Objectives: </strong>Our study aims to propose a 3-step approach - computed tomography (CT) imaging, careful intraoperative assessment, and targeted pathology - to enhance the diagnostic process and optimize the management of TES-related pneumothorax.</p><p><strong>Material and methods: </strong>We retrospectively analyzed 3 cases of recurrent right-sided catamenial pneumothorax in female patients with a history of pelvic endometriosis, managed surgically at the Department of Thoracic Surgery, Medical University of Gdansk, between 2021 and 2024. All included patients underwent video-assisted thoracoscopic surgery (VATS), with comprehensive preoperative CT imaging, intraoperative lesion mapping, and postoperative histopathological examination, improving diagnostic accuracy in TES, with a possible impact on therapeutic results.</p><p><strong>Results: </strong>Chest CT is essential for detecting bullous lesions, aiding in intraoperative identification and surgical treatment. Immunohistochemistry (IHC), assessing estrogen receptor (ER) and CD10 for stromal identification, improves pathological accuracy.</p><p><strong>Conclusions: </strong>This study underlines the diagnostic value of integrating imaging, intraoperative assessment, and targeted histopathology, as well as clear communication between surgeons, radiologists, and pathologists to ensure accurate diagnosis and an improved therapeutic process for patients in clinical practice.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Elżbieta Iskierka-Jażdżewska, Klaudia Zielonka, Bartosz Puła, Agnieszka Chudy, Monika Kustra, Beata Brodacka, Edyta Subocz, Alina Urbanowicz, Dominika Wiśniewska-Organek, Anna Dąbrowska-Iwanicka, Aneta Kozak-Białek, Natalia Leończuk, Ewa Łuksza, Mirosław Markiewicz, Marta Morawska, Marta Oller, Sławomir Radwański, Agnieszka Szeremet, Waldemar Tomczak, Tomasz Górecki, Tomasz Stokłosa, Krzysztof Jamroziak
{"title":"Efficacy of continuous ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia with high-burden and low-burden TP53 mutations: Multicenter retrospective analysis of the Polish Adult Leukemia Group (PALG).","authors":"Elżbieta Iskierka-Jażdżewska, Klaudia Zielonka, Bartosz Puła, Agnieszka Chudy, Monika Kustra, Beata Brodacka, Edyta Subocz, Alina Urbanowicz, Dominika Wiśniewska-Organek, Anna Dąbrowska-Iwanicka, Aneta Kozak-Białek, Natalia Leończuk, Ewa Łuksza, Mirosław Markiewicz, Marta Morawska, Marta Oller, Sławomir Radwański, Agnieszka Szeremet, Waldemar Tomczak, Tomasz Górecki, Tomasz Stokłosa, Krzysztof Jamroziak","doi":"10.17219/acem/215822","DOIUrl":"https://doi.org/10.17219/acem/215822","url":null,"abstract":"<p><strong>Background: </strong>TP53 gene aberrations, including deletions (del(17p)) and mutations, are the strongest predictors of shorter response duration and survival with most therapies for chronic lymphocytic leukemia (CLL). However, the impact of isolated TP53 mutations (without concomitant deletion of the 2nd allele) on outcomes of treatment with Bruton tyrosine kinase inhibitors remains less clear, especially in the context of low-burden mutations.</p><p><strong>Objectives: </strong>This retrospective analysis aimed to assess the efficacy of ibrutinib in patients with relapsed/refractory CLL and TP53 mutations.</p><p><strong>Material and methods: </strong>Patients were selected from a large observational study conducted by the Polish Adult Leukemia Group (PALG) based on the following criteria: the presence of a lowor high-burden TP53 mutation detected by next-generation sequencing (NGS), the absence of del(17p), and treatment with ibrutinib.</p><p><strong>Results: </strong>Of the 468 patients tested using NGS, isolated TP53 mutations were identified in 76 patients, 25 of whom received ibrutinib. This cohort included 13 patients with high-burden mutations (variant allele frequency (VAF) ≥10%) and 12 with low-burden mutations (VAF < 10%). After a median follow-up of 19 months (range: 1-40 months), the best overall response rate (ORR) in the entire study cohort was 84%, with a median progression-free survival (PFS) of 21 months and a median overall survival (OS) of 21 months. There were no statistically significant differences in PFS or OS between the highand low-burden groups (hazard ratio (HR) = 0.74 (95% confidence interval (95% CI): 0.28-2.01); p = 0.559 and HR = 0.75 (95% CI: 0.28-2.01), respectively).</p><p><strong>Conclusions: </strong>In patients with isolated TP53 mutations, the efficacy of ibrutinib did not appear to differ according to mutational burden.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"HDL-related inflammatory biomarkers are associated with sleep disorders: Evidence from a cross-sectional NHANES study.","authors":"Lutong Gan, Yixian Cai, Xian Shi, Simeng Feng, Tuzhi Wang, Zerui You, Jiyang Pan","doi":"10.17219/acem/214708","DOIUrl":"https://doi.org/10.17219/acem/214708","url":null,"abstract":"<p><strong>Background: </strong>Sleep disorders are common and heterogeneous conditions associated with systemic inflammation. They can impair quality of life and increase disease burden. Currently, studies investigating the association between sleep disorders and high-density lipoprotein (HDL)-related inflammatory biomarkers are lacking.</p><p><strong>Objectives: </strong>This study aimed to explore the associations between HDL-related inflammatory biomarkers and sleep disorders.</p><p><strong>Material and methods: </strong>This study utilized data from the National Health and Nutrition Examination Survey (NHANES; 2005-2014). Multivariable logistic regression models were applied to explore the associations between HDL-related inflammatory biomarkers, including platelet-to-HDL ratio (PHR), lymphocyte-to-HDL ratio (LHR), neutrophil-to-HDL ratio (NHR), and monocyte-to-HDL ratio (MHR), and the prevalence of sleep disorders and sleep duration. Subgroup analyses were conducted to investigate potential interactions. In addition, the nonlinear relationship between these inflammatory biomarkers and the likelihood of sleep disorders was assessed using restricted cubic spline (RCS) models. Finally, the robustness of the observed associations was examined through sensitivity analyses.</p><p><strong>Results: </strong>A total of 23,045 individuals were included. In the fully adjusted models, higher MHR (odds ratio (OR) = 1.33; 95% confidence interval (95% CI): 1.11-1.60), NHR (OR = 1.25; 95% CI: 1.04-1.49), LHR (OR = 1.24; 95% CI: 1.05-1.48), and PHR (OR = 1.18; 95% CI: 1.00-1.39) were positively associated with an increased prevalence of sleep disorders. The RCS analysis revealed linear relationships between these inflammatory biomarkers and the likelihood of sleep disorders (all p for nonlinearity >0.05). Subgroup analyses indicated that sex and marital status significantly interacted with all 4 indices (all p for interaction <0.05). Compared with individuals with the recommended sleep duration (7-9 h/day), those with short (<7 h/day) and long (>9 h/day) sleep durations had elevated NHR levels.</p><p><strong>Conclusions: </strong>This study revealed a linear association between HDL-related inflammatory biomarkers and sleep disorders. Moreover, sex and marital status modified the associations of all 4 indices with sleep disorders. In addition, these inflammatory biomarkers were associated with sleep duration.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reporting machine learning studies in clinical research: Practical guidelines for transparent and reproducible analysis.","authors":"Łukasz Lewandowski, Kinga Gostomska-Pampuch","doi":"10.17219/acem/225290","DOIUrl":"https://doi.org/10.17219/acem/225290","url":null,"abstract":"<p><p>The expanding use of machine learning (ML) in clinical research has highlighted persistent methodological weaknesses that undermine the validity and interpretability of reported findings. Common issues include data leakage, inappropriate validation strategies, unstable model performance, and overinterpretation of predictive results. Importantly, strong predictive accuracy does not necessarily translate into clinical utility or biological insight, and poorly validated models may create a misleading impression of robustness. This editorial proposes a concise set of reporting guidelines to improve transparency, reproducibility, and the critical appraisal of ML-based analyses. The framework emphasizes key elements required for evaluation, including study objectives, data preprocessing, validation design, model development, performance assessment, and interpretation. Additional considerations address domain-specific challenges such as deep learning, missing data, and time-dependent structures. Rather than limiting methodological flexibility, these guidelines establish a minimal reporting standard that enables readers and reviewers to assess the credibility and generalizability of findings. By promoting clarity and completeness in reporting, they aim to reduce bias, improve reproducibility, and support the responsible integration of ML methods into clinical research.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From \"data available upon request\" to repository-based sharing: A practical framework for biomedical journals.","authors":"Marek Misiak, Donata Kurpas","doi":"10.17219/acem/235706","DOIUrl":"https://doi.org/10.17219/acem/235706","url":null,"abstract":"<p><p>Data sharing has become a cornerstone of open science, promoting transparency, reproducibility, and the efficient reuse of research data. Although many biomedical journals encourage data sharing, policies remain inconsistent and often require data to be available only upon reasonable request, a practice shown to be largely ineffective. This editorial discusses the rationale, principles, and practical implementation of mandatory repository-based data sharing in biomedical journals, using the experience of Advances in Clinical and Experimental Medicine as an implementation case. It outlines the policy's key components, current recommendations, and the editorial team's implementation experience. Exceptions based on legal, ethical, or commercial constraints are also described. Repository-based data sharing is intended to strengthen research transparency, reproducibility, and long-term accessibility while reducing reliance on ineffective 'data available upon request' models. A practical framework combining clear requirements, persistent data deposition, standardized data-availability statements, justified exemptions, and active editorial support may facilitate wider adoption of FAIR (Findable, Accessible, Interoperable, Reusable) data practices across biomedical journals.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Łukasz Nowak, Jan Łaszkiewicz, Wojciech Andrzej Tomczak, Łukasz Biesiadecki, Joanna Chorbińska, Adam Kruczek, Adam Gurwin, Patryk Patrzałek, Jakub Karwacki, Francesco Del Giudice, Benjamin I Chung, Bartosz Małkiewicz, Tomasz Szydelko, Maciej Guziński, Wojciech Krajewski
{"title":"Kidney function changes following percutaneous cryoablation of renal tumors: A single-center cohort study.","authors":"Łukasz Nowak, Jan Łaszkiewicz, Wojciech Andrzej Tomczak, Łukasz Biesiadecki, Joanna Chorbińska, Adam Kruczek, Adam Gurwin, Patryk Patrzałek, Jakub Karwacki, Francesco Del Giudice, Benjamin I Chung, Bartosz Małkiewicz, Tomasz Szydelko, Maciej Guziński, Wojciech Krajewski","doi":"10.17219/acem/217095","DOIUrl":"https://doi.org/10.17219/acem/217095","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous cryoablation (PCA) is a minimally invasive treatment modality for renal cell carcinoma (RCC) that is often implemented in patients with impaired renal function. However, this procedure inevitably results in the loss of functional renal parenchyma.</p><p><strong>Objectives: </strong>The objective was to establish the influence of PCA on renal function, presented as a difference in estimated glomerular filtration rate (eGFR).</p><p><strong>Material and methods: </strong>This study included patients treated with PCA of renal tumors at 1 institution between June 2023 and February 2025. Creatinine was measured 1 day before the procedure and ≥3 months after. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease (MDRD) equation. Mean differences in eGFR were assessed for the entire cohort and subgroups. Correlation analyses were performed to assess the relationship between eGFR reduction and tumor volume/diameter. Multiple linear regression analysis was conducted to identify factors independently associated with the change in eGFR.</p><p><strong>Results: </strong>Ninety-two procedures met inclusion criteria. A minor but statistically significant decrease in mean eGFR was observed (66.8-61.1 mL/min/1.73 m2, p < 0.001). Patients with a solitary kidney showed no significant decline in eGFR (56.6-54.5 mL/min/1.73m2, p = 0.200), while those with CKD ≥ G3 experienced a modest but significant reduction (47.2-43.5 mL/min/1.73 m2, p = 0.004). After excluding cases with >10% eGFR improvement, the mean eGFR decline remained statistically significant (68.0-59.9 mL/min/1.73 m2, p < 0.001). Weak negative correlations were identified between eGFR reduction and both tumor volume (r = -0.24, p = 0.024) and tumor diameter (r = -0.21, p = 0.042). Finally, previous partial nephrectomy (PN) was associated with better eGFR preservation after PCA in multiple linear regression analysis (p = 0.014).</p><p><strong>Conclusions: </strong>Our findings support the nephron-sparing nature of PCA, which is a safe treatment modality of RCC, especially in patients with significant primary comorbidities.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michał Czapla, Adrian Kwaśny, Joanna Popiołek-Kalisz, Małgorzata Słoma-Krześlak, Grzegorz Kostelecki, Klaudia Wiśniewska, Szymon Warzecha, Anna Brończyk-Puzoń, Izabella Uchmanowicz, Piotr Jankowski
{"title":"Diet and nutrition in chronic heart failure: A scientific statement of the Polish Society of Dietetics.","authors":"Michał Czapla, Adrian Kwaśny, Joanna Popiołek-Kalisz, Małgorzata Słoma-Krześlak, Grzegorz Kostelecki, Klaudia Wiśniewska, Szymon Warzecha, Anna Brończyk-Puzoń, Izabella Uchmanowicz, Piotr Jankowski","doi":"10.17219/acem/225017","DOIUrl":"https://doi.org/10.17219/acem/225017","url":null,"abstract":"<p><p>Poor nutritional status and suboptimal dietary patterns are strongly associated with adverse outcomes in patients with chronic heart failure (CHF), including increased mortality, reduced functional capacity, and a higher risk of hospitalization. This scientific statement from the Polish Society of Dietetics summarizes the current evidence and provides clinically oriented guidance on the role of nutrition in the management of CHF. It outlines the key components of nutritional care across the spectrum of CHF, including screening, assessment, dietary strategies, and supplementation. The main features of evidence-based nutritional management in CHF include: 1) routine nutritional screening using validated tools and structured assessment incorporating the GLIM criteria; 2) identification of malnutrition, cachexia, sarcopenia, and sarcopenic obesity; 3) individualized dietary management tailored to the HF phenotype and clinical status; 4) prioritization of dietary patterns rich in plant-based and minimally processed foods, with the Mediterranean diet as the dietary model supported by the strongest evidence; 5) avoidance of excessive sodium intake and unnecessary fluid restriction in stable patients; 6) ensuring adequate energy intake and protein intake to preserve lean body mass; and 7) targeted, rather than routine, use of micronutrient supplementation, with particular consideration of iron deficiency.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adrian Kwaśny, Małgorzata Słoma-Krześlak, Grzegorz Kostelecki, Anna Maria Rychter, Maria Brzegowy, Małgorzata Jeziorek, Matylda Kręgielska-Narożna, Ewa Lange, Iwona Boniecka, Aleksander Prejbisz, Piotr Dobrowolski, Michał Czapla
{"title":"Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.","authors":"Adrian Kwaśny, Małgorzata Słoma-Krześlak, Grzegorz Kostelecki, Anna Maria Rychter, Maria Brzegowy, Małgorzata Jeziorek, Matylda Kręgielska-Narożna, Ewa Lange, Iwona Boniecka, Aleksander Prejbisz, Piotr Dobrowolski, Michał Czapla","doi":"10.17219/acem/235937","DOIUrl":"https://doi.org/10.17219/acem/235937","url":null,"abstract":"<p><p>Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists, have transformed obesity treatment by producing substantial weight loss and improving cardiometabolic outcomes. However, their therapeutic effects are accompanied by nutritional challenges, including reduced energy intake, gastrointestinal adverse effects, loss of lean mass or fat-free mass, and the risk of inadequate protein and micronutrient intake. This scientific statement of the Polish Society of Dietetics (PTD) summarizes current evidence and provides clinical guidance on nutritional care during incretin-based therapy for obesity. The statements were developed through multidisciplinary expert synthesis and consensus; direct nutrition-specific evidence remains limited, and no formal evidence-grading system was applied. The main features of evidence-informed nutritional care during incretin-based therapy include: 1) structured baseline nutritional assessment and ongoing monitoring of dietary intake, appetite, gastrointestinal tolerance, and body composition; 2) early identification of nutritional risk, including inadequate protein intake, micronutrient insufficiency, dehydration, and excessive loss of lean mass or fat-free mass; 3) individualized dietary strategies supporting adequate nutrient intake and treatment tolerance; 4) preservation of lean mass and muscle function through appropriate protein intake and regular resistance exercise; 5) use of Mediterranean, Dietary Approaches to Stop Hypertension (DASH), or appropriately planned plant-based dietary patterns adapted to individual clinical needs; 6) targeted rather than routine nutritional supplementation based on documented deficiency or increased clinical risk; and 7) integration of registered dietitians within multidisciplinary obesity care pathways. Future research should evaluate the effects of structured dietitian-led interventions on body composition, nutritional status, treatment adherence, and long-term clinical outcomes during incretin-based therapy.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}